Immunochina won the 2018 Billboard • China's 50 Most Valuable Investment Enterprises 09-212018

Learn More

Immunochina CAR-T therapy for new indication’s submission was officially accepted by CFDA 08-082018

Learn More

Immunochina CAR-T therapy clinical data unveiled at ASCO: 3-month complete remission rate of 86% 06-042018

Learn More

Chairman of Immunochina, Dr. He Ting, gave general assembly speech and announced donation feedback for Tsinghua x-lab on the fifth anniversary since Tsinghua x-lab’s establishment 05-282018

Learn More

Immunochina became one of the 10 most noteworthy innovative pharmaceuticals companies in China in 2018 05-252018

Learn More